Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments. Today, the Company has approximately 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Type
Public
HQ
Gent, BE
Founded
2001
Employees
344 (est)
Ablynx was founded in 2001 and is headquartered in Gent, BE

Key People at Ablynx

William Jenkins

William Jenkins

Team Member
Russell Greig

Russell Greig

Team Member
Peter Fellner

Peter Fellner

Chairman of the Board
Frank Landolt

Frank Landolt

IP and legal counsel
Bo Jesper Hansen

Bo Jesper Hansen

Team Member
Guido Gielen

Guido Gielen

VP Human Resources

Ablynx Locations

Gent, BE

Ablynx Metrics

Ablynx Summary

Market capitalization

€585 B

Closing share price

€9.62
Ablynx's latest market capitalization is €585 B.

Ablynx Market Value History

Ablynx Company Life

You may also be interested in